Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qianwang Ma

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
NPJ Precision Oncology|December 10, 2020
Super-enhancer in prostate cancer: transcriptional disorders and therapeutic targetsXuanrong Chen, Qianwang Ma, Zhiqun Shang, et al.
Translational Andrology and Urology|March 15, 2021
A narrative review of proteolytic targeting chimeras (PROTACs): future perspective for prostate cancer therapyXuanrong Chen, Haishan Shen, Yi Shao, et al.
Frontiers in Genetics|June 10, 2024
Causal relationship between anti-inflammatory drugs and cancer: a pan-cancer study with Mendelian randomizationShen Gao, Guojiang Wei, Qianwang Ma, et al.
Journal of Cancer|January 14, 2021
Increased expression of CELSR3 indicates a poor prognostic factor for Prostate CancerXuanrong Chen, Qianwang Ma, Yixi Liu, et al.
Frontiers in Genetics|May 13, 2022
Assessing the Potential Prognostic and Immunological Role of TK1 in Prostate CancerHui Xie, Linpei Guo, Zhun Wang, et al.
Discover Oncology|October 5, 2024
NFYA-mediated promotion of castration-resistant prostate cancer progression through EGR4 regulationGuijiang Sun, Yi Shao, Qianwang Ma, et al.
Cell Death Discovery|September 9, 2023
YAP is required for prostate development, regeneration, and prostate stem cell functionHui Xie, Linpei Guo, Qianwang Ma, et al.
Journal of Cancer|January 10, 2022
Downregulation of LOX promotes castration-resistant prostate cancer progression via IGFBP3Xuanrong Chen, Yi Shao, Wanqing Wei, et al.
Cell Death & Disease|April 24, 2023
Post-transcriptional modification of m<sup>6</sup>A methylase METTL3 regulates ERK-induced androgen-deprived treatment resistance prostate cancerYang Li, Shimiao Zhu, Yutong Chen, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
NPJ Precision Oncology|December 10, 2020
Super-enhancer in prostate cancer: transcriptional disorders and therapeutic targetsXuanrong Chen, Qianwang Ma, Zhiqun Shang, et al.
Translational Andrology and Urology|March 15, 2021
A narrative review of proteolytic targeting chimeras (PROTACs): future perspective for prostate cancer therapyXuanrong Chen, Haishan Shen, Yi Shao, et al.
Frontiers in Genetics|June 10, 2024
Causal relationship between anti-inflammatory drugs and cancer: a pan-cancer study with Mendelian randomizationShen Gao, Guojiang Wei, Qianwang Ma, et al.
Journal of Cancer|January 14, 2021
Increased expression of CELSR3 indicates a poor prognostic factor for Prostate CancerXuanrong Chen, Qianwang Ma, Yixi Liu, et al.
Frontiers in Genetics|May 13, 2022
Assessing the Potential Prognostic and Immunological Role of TK1 in Prostate CancerHui Xie, Linpei Guo, Zhun Wang, et al.
Discover Oncology|October 5, 2024
NFYA-mediated promotion of castration-resistant prostate cancer progression through EGR4 regulationGuijiang Sun, Yi Shao, Qianwang Ma, et al.
Cell Death Discovery|September 9, 2023
YAP is required for prostate development, regeneration, and prostate stem cell functionHui Xie, Linpei Guo, Qianwang Ma, et al.
Journal of Cancer|January 10, 2022
Downregulation of LOX promotes castration-resistant prostate cancer progression via IGFBP3Xuanrong Chen, Yi Shao, Wanqing Wei, et al.
Cell Death & Disease|April 24, 2023
Post-transcriptional modification of m<sup>6</sup>A methylase METTL3 regulates ERK-induced androgen-deprived treatment resistance prostate cancerYang Li, Shimiao Zhu, Yutong Chen, et al.
Pageof 1